🧬 Mark Kotter - bit.bio - Part 2 | Navigating Between the Clinical & Research Worlds | Lessons in Combining Different Fields | The Evolution of Cell Therapies | Transitioning from Academia to Entrepr

Part 2 of 4. My guest today is Mark Kotter, neurosurgeon, stem cell biologist, and CEO and Founder of bit.bio. Bit.bio is an award-winning human synthetic biology company providing human cells for research, drug discovery and cell therapy. Bit.bio applies a patented safe harbor gene-targeting approach to inducibly express transcription factor combinations that reprogram human induced pluripotent stem cells into highly defined and mature human cell types.